Anika Therapeutics, Inc. (ANIK) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Win; EPS growth Lose.
44/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 2 wins, 10 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseANIK / S&P 0.90% / 15.20% |
LoseANIK / S&P 5.33% / 15.00% |
LoseANIK / S&P -93.48% / 50.40% |
| 2026-Q11/3 |
WinANIK / S&P 50.88% / -4.33% |
LoseANIK / S&P -0.67% / 11.30% |
LoseANIK / S&P -79.53% / 27.70% |
| 2025-Q40/3 |
LoseANIK / S&P 2.23% / 2.65% |
LoseANIK / S&P -5.91% / 9.00% |
LoseANIK / S&P -80.16% / 13.40% |
| 2025-Q31/3 |
LoseANIK / S&P -11.15% / 8.12% |
WinANIK / S&P 30.55% / 4.61% |
LoseANIK / S&P -65.81% / 13.45% |
| 2025-Q21/3 |
LoseANIK / S&P -29.61% / 10.94% |
WinANIK / S&P 16.51% / 4.83% |
LoseANIK / S&P -18.18% / 10.63% |
| 2025-Q10/3 |
LoseANIK / S&P -8.69% / -4.27% |
LoseANIK / S&P 4.61% / 4.98% |
LoseANIK / S&P -26.48% / 10.57% |
| 2024-Q40/3 |
LoseANIK / S&P -33.36% / 2.41% |
LoseANIK / S&P -0.73% / 5.25% |
LoseANIK / S&P -32.21% / 6.15% |
| 2024-Q31/3 |
LoseANIK / S&P -2.49% / 5.89% |
LoseANIK / S&P -28.53% / 5.89% |
WinANIK / S&P 292.90% / 6.11% |
| 2024-Q21/3 |
LoseANIK / S&P -0.28% / 4.28% |
LoseANIK / S&P -17.87% / 5.38% |
WinANIK / S&P 230.72% / 5.12% |
| 2024-Q12/3 |
WinANIK / S&P 12.09% / 10.56% |
LoseANIK / S&P -2.75% / 5.71% |
WinANIK / S&P 240.91% / 5.59% |
| 2023-Q42/3 |
WinANIK / S&P 21.63% / 11.69% |
LoseANIK / S&P 6.12% / 6.81% |
WinANIK / S&P 448.54% / 7.78% |
| 2023-Q31/3 |
LoseANIK / S&P -28.29% / -3.27% |
LoseANIK / S&P -20.68% / 7.52% |
WinANIK / S&P 55.05% / -5.03% |
| 2023-Q21/3 |
LoseANIK / S&P -9.54% / 8.74% |
LoseANIK / S&P -21.10% / 9.50% |
WinANIK / S&P 101.32% / -8.57% |
| 2023-Q11/3 |
LoseANIK / S&P -2.97% / 7.50% |
LoseANIK / S&P -23.39% / 10.77% |
WinANIK / S&P 1300.00% / -15.69% |
| 2022-Q41/3 |
WinANIK / S&P 24.37% / 7.56% |
LoseANIK / S&P -22.98% / 11.88% |
LoseANIK / S&P -455.17% / -17.99% |
| 2022-Q32/3 |
WinANIK / S&P 6.63% / -4.88% |
LoseANIK / S&P 5.37% / 13.47% |
WinANIK / S&P 165.85% / -1.41% |
| 2022-Q21/3 |
WinANIK / S&P -11.11% / -16.10% |
LoseANIK / S&P 10.88% / 13.71% |
LoseANIK / S&P -15.56% / 11.04% |
| 2022-Q11/3 |
LoseANIK / S&P -29.92% / -4.60% |
WinANIK / S&P 16.11% / 15.97% |
LoseANIK / S&P -94.18% / 42.23% |
| 2021-Q40/3 |
LoseANIK / S&P -15.81% / 11.03% |
LoseANIK / S&P 13.29% / 15.00% |
LoseANIK / S&P -117.16% / 96.40% |
| 2021-Q31/3 |
LoseANIK / S&P -1.69% / 0.58% |
WinANIK / S&P 13.42% / 10.77% |
LoseANIK / S&P 28.12% / 69.42% |
| 2021-Q21/3 |
LoseANIK / S&P 6.13% / 8.55% |
WinANIK / S&P 8.98% / 6.58% |
LoseANIK / S&P -216.88% / 51.81% |
| 2021-Q11/3 |
LoseANIK / S&P -9.88% / 6.17% |
WinANIK / S&P 3.25% / -1.06% |
LoseANIK / S&P -195.45% / 7.39% |
| 2020-Q42/3 |
WinANIK / S&P 27.89% / 12.15% |
WinANIK / S&P 13.83% / -3.72% |
LoseANIK / S&P -189.42% / -33.42% |
| 2020-Q31/3 |
LoseANIK / S&P -6.20% / 8.93% |
WinANIK / S&P 14.09% / -2.04% |
LoseANIK / S&P -114.88% / -27.10% |
| 2020-Q22/3 |
WinANIK / S&P 30.51% / 20.54% |
WinANIK / S&P 15.30% / -0.46% |
LoseANIK / S&P -62.25% / -27.11% |
| 2020-Q12/3 |
LoseANIK / S&P -44.24% / -19.60% |
WinANIK / S&P 14.92% / 3.47% |
WinANIK / S&P -3.41% / -14.75% |
| 2019-Q42/3 |
LoseANIK / S&P -5.54% / 9.07% |
WinANIK / S&P 8.58% / 5.36% |
WinANIK / S&P 47.66% / 2.99% |
| 2019-Q32/3 |
WinANIK / S&P 35.13% / 1.70% |
LoseANIK / S&P 3.53% / 5.02% |
WinANIK / S&P 67.97% / 0.21% |
| 2019-Q22/3 |
WinANIK / S&P 34.33% / 4.30% |
LoseANIK / S&P 0.46% / 6.64% |
WinANIK / S&P 68.60% / 8.65% |
| 2019-Q11/3 |
LoseANIK / S&P -10.03% / 13.65% |
LoseANIK / S&P -2.05% / 8.12% |
WinANIK / S&P 58.91% / 14.29% |
| 2018-Q40/3 |
LoseANIK / S&P -20.32% / -13.52% |
LoseANIK / S&P -6.93% / 9.05% |
LoseANIK / S&P -39.62% / 18.23% |
| 2018-Q31/3 |
WinANIK / S&P 31.81% / 7.71% |
LoseANIK / S&P -4.23% / 10.21% |
LoseANIK / S&P -39.91% / 19.06% |
| 2018-Q20/3 |
LoseANIK / S&P -35.64% / 3.43% |
LoseANIK / S&P -2.68% / 9.03% |
LoseANIK / S&P -46.46% / 14.46% |
| 2018-Q10/3 |
LoseANIK / S&P -7.77% / -0.76% |
LoseANIK / S&P 6.52% / 7.68% |
LoseANIK / S&P -37.68% / 12.46% |
| 2017-Q41/3 |
LoseANIK / S&P -7.05% / 6.64% |
WinANIK / S&P 9.71% / 7.03% |
LoseANIK / S&P -1.40% / 13.82% |
| 2017-Q32/3 |
WinANIK / S&P 17.55% / 4.48% |
WinANIK / S&P 6.83% / 5.68% |
LoseANIK / S&P -8.58% / 17.57% |
| 2017-Q22/3 |
WinANIK / S&P 13.58% / 3.09% |
WinANIK / S&P 7.66% / 4.83% |
LoseANIK / S&P -1.31% / 17.74% |
| 2017-Q11/3 |
LoseANIK / S&P -11.27% / 6.07% |
WinANIK / S&P 4.73% / 3.67% |
LoseANIK / S&P -7.17% / 13.32% |
| 2016-Q41/3 |
LoseANIK / S&P 2.32% / 3.82% |
WinANIK / S&P 11.16% / 2.09% |
LoseANIK / S&P 6.97% / 7.05% |
| 2016-Q32/3 |
LoseANIK / S&P -10.81% / 3.85% |
WinANIK / S&P 23.65% / 0.20% |
WinANIK / S&P 27.32% / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ANIK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 122.17% | 20.78% |
| Annualized return | 122.17% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ANIK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -51.87% | 83.14% |
| Annualized return | -13.61% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | ANIK total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -56.53% | 319.30% |
| Annualized return | -7.99% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TREACE MEDICAL CONCEPTS, INC. (TMCI) | United States | $0.297B | -4.32 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| PRO DEX INC (PDEX) | United States | $0.234B | 13.64 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Neuronetics, Inc. (STIM) | United States | $0.216B | -3.25 |